Clinical trials: HAI
Hepatocellular Carcinoma
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma.
- Trial name
- NCT06519578
- Testing
- hepatic artery infusion chemotherapy
- Where
- 2 sites in China
- Volunteers
- 1,115 people
- Sponsor
- RenJi Hospital
Hepatic Metastases, Colon Cancer
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus…
- Conditions
- Hepatic Metastases, Colon Cancer, Rectal Cancer
- Trial name
- NCT00200200
- Testing
- Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nosocomial Infections
Efficacy of Copper in Reducing Health-Acquired Infections in a Pediatric Intensive Care Unit
Healthcare-acquired infections (HAI) cause substantial patient morbidity and mortality. Commonly touched items in the patient care environment harbor microorganisms that may contribute to HAI risk.
- Trial name
- NCT01678612
- Testing
- Copper-alloy surfaced objects
- Where
- Chile
- Volunteers
- 1,012 people
- Sponsor
- Codelco
Hepatocellular Carcinoma
A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world and causes death of about 600000~1000000 people each year.
- Trial name
- SOON (NCT01997957)
- Testing
- S-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Nosocomial Infection
New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn
This study aims to evaluate new dosage of inflammatory markers or new inflammatory markers for the diagnosis of nosocomial bacterial infection.
- Trial name
- NOSODIAG (NCT00701948)
- Where
- 2 sites in France
- Volunteers
- 240 people
- Sponsor
- University Hospital, Strasbourg, France
Nosocomial Infection
Healthcare-Associated Infections in Ukraine and the Activity of 4-Thiazolidinone Derivatives Against Related Pathogens
The goal of this observational study is to evaluate the species spectrum and biological properties of bacterial and fungal pathogens causing healthcare-associated infections (HAIs) and to investigate the antimicrobial activity of…
- Trial name
- HAIsUA (NCT06508398)
- Testing
- Microbiological Diagnostic Testing
- Where
- Ukraine
- Volunteers
- 250 people
- Sponsor
- Danylo Halytsky Lviv National Medical University
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Compare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab plus apatinib in hepatocellular carcinoma with portal vein invasion.
- Trial name
- NCT05198609
- Testing
- FOLFOX-HAIC, Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Enterobacteriaceae Infections, Hospital-Acquired Infection
Nosocomial Outbreak of BHRe in an Intensive Care Unit During SARS-CoV-2 Pandemic
Multidrug Resistant (MDR) bacteria have become a major worldwide public health challenge and hospitals are now increasingly faced with management of local outbreaks involving such pathogens.
- Trial name
- BHReICU (NCT05055479)
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatocellular Carcinoma (HCC)
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Indication: Hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) stage C. Study Objectives: This study aims to use a prospective single-center single-arm pilot approach to preliminarily obtain data on…
- Trial name
- NCT06685354
- Testing
- hepatic arterial infusion of recombinant human type 5 adenovirus
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Henan Cancer Hospital
Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
This is a prospective, open-label, single-arm phase II study designed to evaluate the efficacy and safety of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in combination with donafenib and pucotenlimab as first-line…
- Trial name
- NCT07353827
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Postoperative Complications, Surgical Site Infection
Hierarchy of Effects of Laboratory Markers and Their Interaction With Comorbidity Concerning Outcome and Personalized Treatment of Trauma Patients in Emergency Care and Rehabilitation
At least ten percent of trauma patients suffer from any sort of complication. The study aims to identify a risk factor profile to early identify trauma patients at risk.
- Conditions
- Postoperative Complications, Surgical Site Infection, Wound Infection, Non-healing Wound
- Trial name
- HELICOPTER (NCT06758427)
- Where
- Germany
- Volunteers
- 2,300 people
- Sponsor
- Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu
Blood Stream Infection
Topical Emollient Therapy
Almost all (99%) of the neonatal deaths occur in lower and middle income countries. Most of these deaths are attributable to prematurity and infection.
- Trial name
- NCT01396642
- Testing
- Topical Emollient
- Where
- 2 sites in Pakistan
- Volunteers
- 258 people
- Sponsor
- Aga Khan University
Advanced Biliary Tract Cancer
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma.
- Trial name
- NCT04217954
- Testing
- OXA, 5-FU and bevacizumab plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University
Coronavirus Infectious Disease (COVID-19), Nosocomial Infection
NOSOcomial COVID-19 in ICU (NOSOCOVID)
The current global pandemic at COVID-19 is a major public health issue. Transmission of the virus is primarily through direct and close person-to-person contact.
- Conditions
- Coronavirus Infectious Disease (COVID-19), Nosocomial Infection, Nosocomial COVID-19
- Trial name
- NOSOCOVID (NCT04659356)
- Testing
- Patients admitted in Intensive Care Units
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Nantes University Hospital
Surgical Site Infections, Nosocomial Infection
Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures
This is a Phase 2 single-center, open-label, single-arm, study of a microbiological endpoint using antimicrobial photodynamic therapy (aPDT) for nasal disinfection in all patients (universal) presenting for surgery at an acute…
- Conditions
- Surgical Site Infections, Nosocomial Infection, Healthcare Associated Infections
- Trial name
- BENEFIT-PDT (NCT05090657)
- Testing
- methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
- Where
- United States
- Volunteers
- 322 people
- Sponsor
- Ondine Biomedical Inc.
Hepatocellular Carcinoma
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.
- Trial name
- NCT05617430
- Testing
- HAIC, Sintilimab, Bevacizumab Biosimilar IBI305
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Unrescetable Hepatocellular Carcinoma
HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
- Trial name
- NCT05821361
- Testing
- HAIC+Cadonilimab+Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital